Physician

Amanda Yant Laubenthal, D.O.

According to 2025 Medicare claims, Amanda Laubenthal, D.O. (NPI: 1235336355) practices medical oncology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Lawrence, PA. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATION INC (NPI: 1861469223; TIN: 251762980) and primary practice location at 16105-3210.

Laubenthal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 305 traditional Medicare patients, billed 892 HCPCS/CPT codes, and received $60,027 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,865 prescription claims across 286 beneficiaries totaling $5,504,082 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 33 claims. Open Payments data shows 1 records totaling $14. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $466,011 to $5,504,082. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,264 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	192	779	$68,015
2016	275	971	$81,227
2017	296	784	$59,496
2018	219	926	$71,823
2019	317	1,127	$82,951
2020	285	1,012	$61,519
2021	352	1,088	$90,610
2022	310	979	$78,538
2023	320	796	$63,512
2024	305	892	$60,027

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	76	581	$466,011
2016	117	845	$558,282
2017	148	628	$254,146
2018	161	1,006	$831,729
2019	252	1,555	$1,642,661
2020	234	1,552	$3,048,005
2021	297	2,046	$5,156,181
2022	291	1,904	$5,125,311
2023	299	1,853	$4,672,066
2024	286	1,865	$5,504,082

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	49	$41,620
2016	N/R	115	$25,684
2017	N/R	N/R	N/R
2018	N/R	49	$3,906
2019	N/R	36	$5,260
2020	N/R	N/R	N/R
2021	N/R	11	$1,451
2022	N/R	26	$765
2023	N/R	12	$6,102
2024	N/R	33	$718

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	90	298	$104
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	52	56	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	113	145	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	123	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	129	190	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	51	1,288	$646,527
Pomalyst	Pomalidomide	24	672	$569,330
Xtandi	Enzalutamide	32	960	$454,683
Revlimid	Lenalidomide	25	693	$433,982
Ibrance	Palbociclib	25	700	$401,600

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$468
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$14	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amanda Yant Laubenthal, D.O.?

Tedicare shows public-source Medicare data for Amanda Yant Laubenthal, D.O. (NPI 1235336355), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amanda Yant Laubenthal, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amanda Yant Laubenthal, D.O.?

Amanda Yant Laubenthal, D.O. is linked to ONCOLOGY HEMATOLOGY ASSOCIATION INC (billing NPI 1861469223) in the available physician profile data.

Does Amanda Yant Laubenthal, D.O. have Open Payments data?

Amanda Yant Laubenthal, D.O. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.